Results 191 to 200 of about 210,894 (311)
Endometriosis and eating disorders: epidemiology, shared neurobiology, and clinical implications. [PDF]
Di Michele S +7 more
europepmc +1 more source
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Arguments and Analogies: Do Children Have a Right to Know Their Genetic Origins? [PDF]
Charles S.
europepmc +1 more source
Here, we demonstrate that HS1BP3 interacts with Cortactin through a proline‐rich region (PRR3.1) and show that this interaction, and HS1BP3 itself, promote cancer cell proliferation and invasion. Inhibition of this interaction leads to build‐up of TKS5 in multivesicular endosomes and altered secretion of CD63 and CD9, providing an explanation for the ...
Arja Arnesen Løchen +9 more
wiley +1 more source
Neurological diversity and generalizability: building on AMPA receptor imaging advances in long COVID. [PDF]
Rudroff T.
europepmc +1 more source
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata +10 more
wiley +1 more source
Personality disorders and cardiometabolic diseases: A Mendelian randomization study. [PDF]
Yang W, Yang Z, Xi J, Bian C, Cheng Z.
europepmc +1 more source
Quantitative genetic models for partheonogenetic species [PDF]
Gabriel, Wilfried, Jong, Gerdina de
core
Molecular cancer prevention: Intercepting disease
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco +2 more
wiley +1 more source

